LOS ANGELES--(BUSINESS WIRE)--July 11, 2006--Cougar Biotechnology, Inc., a biotechnology company focused on acquiring and developing oncology drug candidates, today announced that the first patient has been enrolled in a Phase I trial of the Company's drug candidate CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, for the treatment of advanced prostate cancer.
